• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

费城染色体断点聚集在22号染色体上一个有限的区域——bcr内。

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

作者信息

Groffen J, Stephenson J R, Heisterkamp N, de Klein A, Bartram C R, Grosveld G

出版信息

Cell. 1984 Jan;36(1):93-9. doi: 10.1016/0092-8674(84)90077-1.

DOI:10.1016/0092-8674(84)90077-1
PMID:6319012
Abstract

We have identified and molecularly cloned 46 kb of human DNA from chromosome 22 using a probe specific for the Philadelphia (Ph') translocation breakpoint domain of one chronic myelocytic leukemia (CML) patient. The DNAs of 19 CML patients were examined for rearrangements on chromosome 22 with probes isolated from this cloned region. In 17 patients, chromosomal breakpoints were found within a limited region of up to 5.8 kb, for which we propose the term "breakpoint cluster region" (bcr). The two patients having no rearrangements within bcr lacked the Ph' chromosome. The highly specific presence of a chromosomal breakpoint within bcr in Ph'-positive CML patients strongly suggests the involvement of bcr in this type of leukemia.

摘要

我们使用针对一名慢性粒细胞白血病(CML)患者费城(Ph')易位断点区域的特异性探针,从22号染色体上鉴定并分子克隆了46 kb的人类DNA。使用从该克隆区域分离的探针,检测了19名CML患者的DNA在22号染色体上的重排情况。在17名患者中,染色体断点位于一个最大为5.8 kb的有限区域内,我们将此区域称为“断点簇区域”(bcr)。在bcr内没有重排的两名患者缺乏Ph'染色体。Ph'阳性CML患者的bcr内染色体断点高度特异性地存在,强烈提示bcr参与了此类白血病的发生。

相似文献

1
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.费城染色体断点聚集在22号染色体上一个有限的区域——bcr内。
Cell. 1984 Jan;36(1):93-9. doi: 10.1016/0092-8674(84)90077-1.
2
Structural organization of the bcr gene and its role in the Ph' translocation.bcr基因的结构组织及其在费城染色体易位中的作用。
Nature. 1985;315(6022):758-61. doi: 10.1038/315758a0.
3
Breakpoints in Philadelphia chromosome (Ph1)-positive leukemias.费城染色体(Ph1)阳性白血病的断点
Jpn J Cancer Res. 1987 Jun;78(6):590-5.
4
Genomic diversity correlates with clinical variation in Ph'-negative chronic myeloid leukaemia.
Nature. 1986;320(6059):281-3. doi: 10.1038/320281a0.
5
Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philadelphia translocations.慢性粒细胞白血病(CML)细胞中具有变异型费城染色体易位的断裂点簇集区(3' bcr)的易位
Cancer Genet Cytogenet. 1987 May;26(1):105-15. doi: 10.1016/0165-4608(87)90138-5.
6
The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia.首个BCR基因内含子在费城染色体阳性白血病中存在断点。
Nucleic Acids Res. 1988 Nov 11;16(21):10069-81. doi: 10.1093/nar/16.21.10069.
7
Undetectable bcr-abl rearrangements in some CML patients are due to a deletion mutation in the bcr gene.一些慢性粒细胞白血病(CML)患者中检测不到bcr-abl重排是由于bcr基因的缺失突变。
Am J Hematol. 1988 May;28(1):33-6. doi: 10.1002/ajh.2830280107.
8
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病中bcr和c-abl基因的独特融合
Cell. 1987 Oct 9;51(1):33-40. doi: 10.1016/0092-8674(87)90007-9.
9
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.慢性粒细胞白血病中与易位断点相邻的c-ab1癌基因的定位。
Nature. 1983;306(5940):239-42. doi: 10.1038/306239a0.
10
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.慢性粒细胞系K562在bcr中有一个断点,并产生一种嵌合的bcr/c-abl转录本。
Mol Cell Biol. 1986 Feb;6(2):607-16. doi: 10.1128/mcb.6.2.607-616.1986.

引用本文的文献

1
Translocations can drive expression changes of multiple genes in regulons covering entire chromosome arms.易位可驱动整个染色体臂调控子中多个基因的表达变化。
Nucleic Acids Res. 2025 Aug 11;53(15). doi: 10.1093/nar/gkaf677.
2
Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.主要骨髓增殖性肿瘤诊断与治疗的当前进展
Cancers (Basel). 2025 May 30;17(11):1834. doi: 10.3390/cancers17111834.
3
Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia.
Neddylation状态决定了慢性粒细胞白血病中酪氨酸激酶抑制剂的治疗敏感性。
Sci Rep. 2025 May 30;15(1):18978. doi: 10.1038/s41598-025-04153-7.
4
Recent Developments in the Synthesis of Benzothiazoles and their Anti-cancer Mechanistic Discoveries.苯并噻唑的合成及其抗癌机制发现的最新进展
Curr Pharm Des. 2025;31(32):2559-2593. doi: 10.2174/0113816128355783250212043621.
5
A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time.一种考虑纵向数据和随时间变化的灵活风险比模式的新治疗模型。
Stat Methods Med Res. 2025 Apr;34(4):683-700. doi: 10.1177/09622802251320793. Epub 2025 Feb 28.
6
Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells.酪氨酸激酶抑制剂疗法可增强干细胞特征,并可能有助于慢性髓性白血病干细胞的存活。
J Clin Med. 2025 Jan 10;14(2):392. doi: 10.3390/jcm14020392.
7
Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 fusion transcripts: a case report and review of the literature.共表达V-e16a2、V-e13a2、e13a2和e14a2融合转录本的慢性粒细胞白血病:一例报告并文献复习
Front Oncol. 2024 Dec 12;14:1518387. doi: 10.3389/fonc.2024.1518387. eCollection 2024.
8
Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy.肿瘤学中新兴的AXL抑制剂:靶向癌症治疗的化学与生物学进展
Anticancer Agents Med Chem. 2025;25(7):460-467. doi: 10.2174/0118715206351185241209053053.
9
Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development.波纳替尼:其研发背后的药物化学史综述
Pharmaceuticals (Basel). 2024 Oct 11;17(10):1361. doi: 10.3390/ph17101361.
10
A Suite of Foundation Models Captures the Contextual Interplay Between Codons.一组基础模型捕捉到密码子之间的上下文相互作用。
bioRxiv. 2024 Oct 13:2024.10.10.617568. doi: 10.1101/2024.10.10.617568.